{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:11:21Z","timestamp":1794964281729,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 109-2320-B-400-021"],"award-info":[{"award-number":["MOST 109-2320-B-400-021"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 105-2628-B-016-002-MY2"],"award-info":[{"award-number":["MOST 105-2628-B-016-002-MY2"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 109-2320-B-016-012"],"award-info":[{"award-number":["MOST 109-2320-B-016-012"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"crossref","award":["NHRI-110A1-MRCO-08212101"],"award-info":[{"award-number":["NHRI-110A1-MRCO-08212101"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019000","name":"Ministry of National Defense Medical Affairs Bureau","doi-asserted-by":"crossref","award":["MAB-110-104"],"award-info":[{"award-number":["MAB-110-104"]}],"id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019000","name":"Ministry of National Defense Medical Affairs Bureau","doi-asserted-by":"crossref","award":["MND-MAB-C04-111016"],"award-info":[{"award-number":["MND-MAB-C04-111016"]}],"id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Flavivirus causes many serious public health problems worldwide. However, licensed DENV vaccine has restrictions on its use, and there is currently no approved ZIKV vaccine. Development of a potent and safe flavivirus vaccine is urgently needed. As a previous study revealed the epitope, RCPTQGE, located on the bc loop in the E protein domain II of DENV, in this study, we rationally designed and synthesized a series of peptides based on the sequence of JEV epitope RCPTTGE and DENV\/ZIKV epitope RCPTQGE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Immune sera were generated by immunization with the peptides which were synthesized by using five copies of RCPTTGE or RCPTQGE and named as JEV-NTE and DV\/ZV-NTE<jats:sub>.<\/jats:sub> Immunogenicity and neutralizing abilities of JEV-NTE or DV\/ZV-NTE-immune sera against flavivirus were evaluated by ELISA and neutralization tests, respectively. Protective efficacy in vivo were determined by passive transfer the immune sera into JEV-infected ICR or DENV- and ZIKV-challenged AG129 mice. In vitro and in vivo ADE assays were used to examine whether JEV-NTE or DV\/ZV-NTE-immune sera would induce ADE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Passive immunization with JEV-NTE-immunized sera or DV\/ZV-NTE-immunized sera could increase the survival rate or prolong the survival time in JEV-challenged ICR mice and reduce the viremia levels significantly in DENV- or ZIKV-infected AG129 mice. Furthermore, neither JEV -NTE- nor DV\/ZV-NTE-immune sera induced antibody-dependent enhancement (ADE) as compared with the control mAb 4G2 both in vitro and in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We showed for the first time that novel bc loop epitope RCPTQGE located on the amino acids 73 to 79 of DENV\/ZIKV E protein could elicit cross-neutralizing antibodies and reduced the viremia level in DENV- and ZIKV-challenged AG129 mice. Our results highlighted that the bc loop epitope could be a promising target for flavivirus vaccine development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-023-00938-y","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T11:02:17Z","timestamp":1686740537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement"],"prefix":"10.1186","volume":"30","author":[{"given":"Li-Chen","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lo","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chou","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Pei","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Jye","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-130X","authenticated-orcid":false,"given":"Ching-Len","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"938_CR1","first-page":"1101","volume-title":"Fields virology","author":"BD Lindenbach","year":"2011","unstructured":"Lindenbach BD, Thiel H-J, Rice CM. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley OM, editors. Fields virology. 5th edn. Philadelphia: Lippincot William & Wilkins; 2011. pp. 1101\u201351.","edition":"5"},{"issue":"10169","key":"938_CR2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","volume":"393","author":"A Wilder-Smith","year":"2019","unstructured":"Wilder-Smith A, et al. Dengue. Lancet. 2019;393(10169):350\u201363.","journal-title":"Lancet"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","volume":"29","author":"BR Murphy","year":"2011","unstructured":"Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587\u2013619.","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"938_CR4","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1602113","volume":"374","author":"LR Petersen","year":"2016","unstructured":"Petersen LR, et al. Zika virus. N Engl J Med. 2016;374(16):1552\u201363.","journal-title":"N Engl J Med"},{"issue":"16","key":"938_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMc1609015","volume":"375","author":"T Dos Santos","year":"2016","unstructured":"Dos Santos T, et al. Zika virus and the Guillain-Barre syndrome\u2014case series from seven countries. N Engl J Med. 2016;375(16):1598\u2013601.","journal-title":"N Engl J Med"},{"issue":"11","key":"938_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa1709481","volume":"378","author":"B Hoen","year":"2018","unstructured":"Hoen B, et al. Pregnancy outcomes after ZIKV infection in French territories in the Americas. N Engl J Med. 2018;378(11):985\u201394.","journal-title":"N Engl J Med"},{"issue":"10107","key":"938_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(17)31450-2","volume":"390","author":"D Baud","year":"2017","unstructured":"Baud D, et al. An update on Zika virus infection. Lancet. 2017;390(10107):2099\u2013109.","journal-title":"Lancet"},{"issue":"13","key":"938_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40265-016-0626-8","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ. Tetravalent dengue vaccine: a review in the prevention of dengue disease. Drugs. 2016;76(13):1301\u201312.","journal-title":"Drugs"},{"issue":"22","key":"938_CR9","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.3390\/molecules26226768","volume":"26","author":"H Norshidah","year":"2021","unstructured":"Norshidah H, Vignesh R, Lai NS. Updates on dengue vaccine and antiviral: where are we heading? Molecules. 2021;26(22):6768.","journal-title":"Molecules"},{"issue":"3","key":"938_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009258","volume":"15","author":"LJ White","year":"2021","unstructured":"White LJ, et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLoS Negl Trop Dis. 2021;15(3): e0009258.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"938_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12275-022-1625-y","volume":"60","author":"J Park","year":"2022","unstructured":"Park J, Kim J, Jang YS. Current status and perspectives on vaccine development against dengue virus infection. J Microbiol. 2022;60(3):247\u201354.","journal-title":"J Microbiol"},{"issue":"6","key":"938_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/pathogens9060470","volume":"9","author":"L Wilken","year":"2020","unstructured":"Wilken L, Rimmelzwaan GF. Adaptive immunity to dengue virus: slippery slope or solid ground for rational vaccine design? Pathogens. 2020;9(6):470.","journal-title":"Pathogens"},{"issue":"9","key":"938_CR13","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1128\/JVI.79.9.5516-5528.2005","volume":"79","author":"JE Blaney Jr","year":"2005","unstructured":"Blaney JE Jr, et al. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005;79(9):5516\u201328.","journal-title":"J Virol"},{"issue":"7","key":"938_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrmicro1690","volume":"5","author":"SS Whitehead","year":"2007","unstructured":"Whitehead SS, et al. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518\u201328.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"938_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/erv.09.139","volume":"9","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, et al. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010;9(2):137\u201347.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"938_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2051013613507862","volume":"2","author":"U Thisyakorn","year":"2014","unstructured":"Thisyakorn U, Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014;2(1):3\u20139.","journal-title":"Ther Adv Vaccines"},{"issue":"2","key":"938_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.micinf.2008.12.004","volume":"11","author":"CH Leng","year":"2009","unstructured":"Leng CH, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288\u201395.","journal-title":"Microbes Infect"},{"issue":"7059","key":"938_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nature03956","volume":"437","author":"GE Nybakken","year":"2005","unstructured":"Nybakken GE, et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. 2005;437(7059):764\u20139.","journal-title":"Nature"},{"issue":"5","key":"938_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nm1240","volume":"11","author":"T Oliphant","year":"2005","unstructured":"Oliphant T, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11(5):522\u201330.","journal-title":"Nat Med"},{"issue":"4","key":"938_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","volume":"166","author":"H Zhao","year":"2016","unstructured":"Zhao H, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166(4):1016\u201327.","journal-title":"Cell"},{"issue":"7545","key":"938_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski A, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520(7545):109\u201313.","journal-title":"Nature"},{"issue":"1","key":"938_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/14760584.2015.961431","volume":"14","author":"DG Widman","year":"2015","unstructured":"Widman DG, Baric RS. Dengue virus envelope protein domain I\/II hinge: a key target for dengue virus vaccine design? Expert Rev Vaccines. 2015;14(1):5\u20138.","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"938_CR23","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1073\/pnas.1317350111","volume":"111","author":"WB Messer","year":"2014","unstructured":"Messer WB, et al. Dengue virus envelope protein domain I\/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci USA. 2014;111(5):1939\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"938_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","volume":"17","author":"W Dejnirattisai","year":"2016","unstructured":"Dejnirattisai W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102\u20138.","journal-title":"Nat Immunol"},{"issue":"196","key":"938_CR25","first-page":"49","volume":"49","author":"AH Fagbami","year":"1987","unstructured":"Fagbami AH, et al. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios. 1987;49(196):49\u201355.","journal-title":"Cytobios"},{"issue":"4","key":"938_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4269\/ajtmh.1980.29.638","volume":"29","author":"SB Halstead","year":"1980","unstructured":"Halstead SB, Porterfield JS, O\u2019Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg. 1980;29(4):638\u201342.","journal-title":"Am J Trop Med Hyg"},{"issue":"6301","key":"938_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","volume":"353","author":"K Stettler","year":"2016","unstructured":"Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823\u20136.","journal-title":"Science"},{"issue":"28","key":"938_CR28","doi-asserted-by":"publisher","first-page":"7852","DOI":"10.1073\/pnas.1607931113","volume":"113","author":"L Priyamvada","year":"2016","unstructured":"Priyamvada L, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA. 2016;113(28):7852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6334","key":"938_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aal4365","volume":"356","author":"SV Bardina","year":"2017","unstructured":"Bardina SV, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175\u201380.","journal-title":"Science"},{"issue":"6","key":"938_CR30","doi-asserted-by":"publisher","first-page":"e00873-13","DOI":"10.1128\/mBio.00873-13","volume":"4","author":"SA Smith","year":"2013","unstructured":"Smith SA, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013;4(6):e00873-13.","journal-title":"MBio"},{"issue":"1","key":"938_CR31","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","volume":"19","author":"A Wilder-Smith","year":"2019","unstructured":"Wilder-Smith A, et al. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2019;19(1):e31\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"938_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002432","volume":"7","author":"C-Y Chiang","year":"2013","unstructured":"Chiang C-Y, et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis. 2013;7(9): e2432.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"938_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006854","volume":"14","author":"Y Simanjuntak","year":"2018","unstructured":"Simanjuntak Y, et al. Ebselen alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. PLoS Pathog. 2018;14(2): e1006854.","journal-title":"PLoS Pathog"},{"issue":"11","key":"938_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188170","volume":"12","author":"MS Hsieh","year":"2017","unstructured":"Hsieh MS, et al. Detection and quantification of dengue virus using a novel biosensor system based on dengue NS3 protease activity. PLoS ONE. 2017;12(11): e0188170.","journal-title":"PLoS ONE"},{"issue":"1","key":"938_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0168-1702(96)01343-3","volume":"44","author":"YL Lin","year":"1996","unstructured":"Lin YL, et al. A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in mice. Virus Res. 1996;44(1):45\u201356.","journal-title":"Virus Res"},{"issue":"5","key":"938_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","volume":"19","author":"L Dai","year":"2016","unstructured":"Dai L, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19(5):696\u2013704.","journal-title":"Cell Host Microbe"},{"issue":"49","key":"938_CR37","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1016\/j.vaccine.2011.09.102","volume":"31","author":"LC Yen","year":"2013","unstructured":"Yen LC, et al. Neurovirulent flavivirus can be attenuated in mice by incorporation of neuron-specific microRNA recognition elements into viral genome. Vaccine. 2013;31(49):5915\u201322.","journal-title":"Vaccine"},{"issue":"1","key":"938_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.str.2017.11.017","volume":"26","author":"J Li","year":"2018","unstructured":"Li J, et al. Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope. Structure. 2018;26(1):51-59.e4.","journal-title":"Structure"},{"issue":"Pt 2","key":"938_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1099\/vir.0.015420-0","volume":"91","author":"H Puerta-Guardo","year":"2010","unstructured":"Puerta-Guardo H, et al. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains. J Gen Virol. 2010;91(Pt 2):394\u2013403.","journal-title":"J Gen Virol"},{"issue":"9","key":"938_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001834","volume":"6","author":"YC Fan","year":"2012","unstructured":"Fan YC, et al. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis. 2012;6(9): e1834.","journal-title":"PLoS Negl Trop Dis"},{"key":"938_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102991","volume":"60","author":"R Shukla","year":"2020","unstructured":"Shukla R, et al. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. EBioMedicine. 2020;60: 102991.","journal-title":"EBioMedicine"},{"issue":"2","key":"938_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000790","volume":"6","author":"SJ Balsitis","year":"2010","unstructured":"Balsitis SJ, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2): e1000790.","journal-title":"PLoS Pathog"},{"issue":"2","key":"938_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.chom.2010.01.004","volume":"7","author":"RM Zellweger","year":"2010","unstructured":"Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010;7(2):128\u201339.","journal-title":"Cell Host Microbe"},{"issue":"11","key":"938_CR44","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1128\/JVI.00216-15","volume":"89","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, et al. Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice. J Virol. 2015;89(11):5847\u201361.","journal-title":"J Virol"},{"key":"938_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ebiom.2019.05.014","volume":"44","author":"VN Camargos","year":"2019","unstructured":"Camargos VN, et al. In-depth characterization of congenital Zika syndrome in immunocompetent mice: antibody-dependent enhancement and an antiviral peptide therapy. EBioMedicine. 2019;44:516\u201329.","journal-title":"EBioMedicine"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00938-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-023-00938-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00938-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:03:55Z","timestamp":1686744235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-023-00938-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/s12929-023-00938-y","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out according to the guidelines outlined by the Council of Agriculture, Executive Yuan, Taiwan, in adherence with the Declaration of Helsinki and US National Institutes of Health Guidelines for the treatment of laboratory animals. The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the National Defense Medical Center (permit no. IACUC-19-320).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}